medRxiv · Nov 21, 2025
The effect of BCG vaccination on adult mortality during the COVID-19 pandemic: a meta-analysis of randomised controlled trials
By Schaltz‐Buchholzer F, Curtis NC, Diacon AH et al.
Abstract Objectives Bacillus Calmette-Guérin (BCG), similar to some other live vaccines, may offer partial protection against unrelated infections. During the COVID-19 pandemic, several trials tested whether BCG provides protection against COVID-19. Design Meta-analysis of randomised placebo-controlled trials which provided mortality data. Setting High-income settings as well as low- and middle-income settings (LMICs). Participants Trial populations were healthcare workers (HCW) or individuals of older age, followed for 6-12 months. Interventions BCG vaccine versus placebo. Main outcome measure Overall mortality and COVID-19 mortality. Results Nine of the 15 RCTs reported at least one death. Trial populations were healthcare workers (4 RCTs) or individuals of older age (5 RCTs), in Europe (5 RCTs) or LMICs (4 RCTs) with a total of 8,169 participants randomly allocated to BCG (18 deaths) and 8,176 to placebo (37 deaths). In a meta-analysis, receiving BCG vs placebo was associated with a 51% (95% CI: 15 to72%) reduction in all-cause mortality. The all-cause mortality RRR was 78% (−3 to 95%) in HCWs (Europe and LMICs) and 43% (95% CI: −6 to 69%) in the elderly. It was 37% (95 CI: −15 to 66%) in Europe and 90% (95% CI: 22 to 99%) in LMICs. The relative reduction of deaths (6 BCG; 12 placebo) from COVID-19 was 50% (95 CI: −33 to 81). Conclusions BCG may have reduced all-cause mortality in the context of the COVID-19 pandemic.